{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T23:55:52Z","timestamp":1790207752135,"version":"4.1.0"},"reference-count":41,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T00:00:00Z","timestamp":1756166400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Liver International"],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background &amp; Aims<\/jats:title>\n                    <jats:p>\n                      Cholangiocarcinoma (CCA) is a rare cancer with limited therapeutic options and a poor prognosis. While first\u2010line combination therapies have improved outcomes, second\u2010line treatment remains challenging. Ivosidenib, an\n                      <jats:italic>IDH1<\/jats:italic>\n                      inhibitor, has shown promise in treating\n                      <jats:italic>IDH1<\/jats:italic>\n                      mutant CCA, but real\u2010world data is limited. This study aims to evaluate ivosidenib's efficacy and safety in a large cohort of patients and compare it with second\u2010line chemotherapy.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This observational, retrospective, multicenter study included patients with advanced\n                      <jats:italic>IDH1<\/jats:italic>\n                      mutant CCA treated with ivosidenib at 11 European institutions from May 2021 to September 2024. The primary endpoint was progression\u2010free survival (PFS); the main secondary objectives were overall survival (OS), disease control rate (DCR), overall response rate (ORR) and safety. As a pre\u2010planned exploratory objective, mPFS and OS of second\u2010line ivosidenib and FOLFOX\/CAPOX were compared by means of inverse probability of treatment weights (IPTW)\u2010adjusted analysis.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The study included 46 patients treated with Ivosidenib; 43.5% received ivosidenib as second line and 56.5% as \u2265\u2009third line. Median PFS and OS were 3.7 (95% CI, 2.2\u201336.5) and 11.5\u2009months (95% CI, 9.5\u201336.5). DCR was 50.0%. Grade \u2265\u20093 adverse events occurred in 8.7% of patients. IPTW\u2010adjusted mPFS was 6.9\u2009months with ivosidenib and 2.1\u2009months with FOLFOX\/CAPOX (HR: 0.36, 95% CI, 0.20\u20130.64,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0005), while the mOS was 15.9 and 9.0\u2009months with ivosidenib and FOLFOX\/CAPOX, respectively (HR: 0.47, 95% CI, 0.23\u20130.96,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0405).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      This study suggests that ivosidenib is a valid option for patients affected by metastatic\n                      <jats:italic>IDH1<\/jats:italic>\n                      mutant CCA after at least one line of standard treatment.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/liv.70295","type":"journal-article","created":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T11:28:13Z","timestamp":1756207693000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Ivosidenib for IDH1\u2010Mutant Intrahepatic Cholangiocarcinoma: Insights From a Multicenter Real\u2010World Study"],"prefix":"10.1111","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9055-5338","authenticated-orcid":false,"given":"Monica","family":"Niger","sequence":"first","affiliation":[{"name":"Medical Oncology Department Fondazione IRCCS Instituto Nazionale dei Tumori di Milano  Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4047-2585","authenticated-orcid":false,"given":"Margherita","family":"Rimini","sequence":"additional","affiliation":[{"name":"Department of Oncology IRCCS San Raffaele Scientific Institute Hospital, Vita\u2010Salute San Raffaele University  Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5416-5383","authenticated-orcid":false,"given":"Florian","family":"Castet","sequence":"additional","affiliation":[{"name":"Gastrointestinal and Endocrine Tumor Unit Vall d'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d'Hebron  Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Melzer","sequence":"additional","affiliation":[{"name":"Internal Medicine 1 University Hospital Ulm  Ulm Germany"},{"name":"Institute of Molecular Oncology and Stem Cell Biology Ulm University Hospital  Ulm Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8322-2842","authenticated-orcid":false,"given":"Mario Domenico","family":"Rizzato","sequence":"additional","affiliation":[{"name":"Department of Oncology Veneto Institute of Oncology IOV\u2010IRCCS  Padua Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiziana","family":"Pressiani","sequence":"additional","affiliation":[{"name":"Medical Oncology and Hematology Unit Humanitas Cancer Center, IRCCS Humanitas Research Hospital  Rozzano Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Lavacchi","sequence":"additional","affiliation":[{"name":"Clinical Oncology Unit Careggi University Hospital  Florence Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Aprile","sequence":"additional","affiliation":[{"name":"Department of Oncology University and General Hospital  Udine Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torsello","family":"Angela","sequence":"additional","affiliation":[{"name":"UOC Oncology, AO San Giovanni  Roma Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiziana","family":"Saladino","sequence":"additional","affiliation":[{"name":"Oncology Unit AST3 Macerata Hospital  Macerata Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noventa","family":"Silvia","sequence":"additional","affiliation":[{"name":"Medical Oncology Fondazione Poliambulanza Istituto Ospedaliero  Brescia Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pasqua","family":"Cito","sequence":"additional","affiliation":[{"name":"Oncologia Medica Ospedale San Pio Di Castellaneta  Taranto Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Pastorino","sequence":"additional","affiliation":[{"name":"Medical Oncology Unit 1 IRCCS Ospedale Policlinico San Martino  Genoa Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Ter\u00e1n\u2010Brage","sequence":"additional","affiliation":[{"name":"Gastrointestinal and Endocrine Tumor Unit Vall d'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d'Hebron  Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Sciortino","sequence":"additional","affiliation":[{"name":"Medical Oncology Department Fondazione IRCCS Instituto Nazionale dei Tumori di Milano  Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8203-1684","authenticated-orcid":false,"given":"Silvia","family":"Camera","sequence":"additional","affiliation":[{"name":"Department of Oncology IRCCS San Raffaele Scientific Institute Hospital, Vita\u2010Salute San Raffaele University  Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8173-824X","authenticated-orcid":false,"given":"Chiara","family":"Pircher","sequence":"additional","affiliation":[{"name":"Medical Oncology Department Fondazione IRCCS Instituto Nazionale dei Tumori di Milano  Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3600-0232","authenticated-orcid":false,"given":"Mara","family":"Persano","sequence":"additional","affiliation":[{"name":"Department of Oncology IRCCS San Raffaele Scientific Institute Hospital, Vita\u2010Salute San Raffaele University  Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Mazzaferro","sequence":"additional","affiliation":[{"name":"Department of Oncology and Hemato\u2010Oncology University of Milan  Milan Italy"},{"name":"Fondazione IRCCS Istituto Nazionale Tumori HPB Surgery and Liver Transplantation  Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Foti","sequence":"additional","affiliation":[{"name":"Department of Oncology IRCCS San Raffaele Scientific Institute Hospital, Vita\u2010Salute San Raffaele University  Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kreina Sharela","family":"Vega","sequence":"additional","affiliation":[{"name":"Gastrointestinal and Endocrine Tumor Unit Vall d'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d'Hebron  Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J.","family":"Ettrich","sequence":"additional","affiliation":[{"name":"Internal Medicine 1 University Hospital Ulm  Ulm Germany"},{"name":"Institute of Molecular Oncology and Stem Cell Biology Ulm University Hospital  Ulm Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Antonuzzo","sequence":"additional","affiliation":[{"name":"Clinical Oncology Unit Careggi University Hospital  Florence Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenza","family":"Rimassa","sequence":"additional","affiliation":[{"name":"Medical Oncology and Hematology Unit Humanitas Cancer Center, IRCCS Humanitas Research Hospital  Rozzano Italy"},{"name":"Department of Biomedical Sciences Humanitas University  Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Lonardi","sequence":"additional","affiliation":[{"name":"Department of Oncology Veneto Institute of Oncology IOV\u2010IRCCS  Padua Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"Perkhofer","sequence":"additional","affiliation":[{"name":"Internal Medicine 1 University Hospital Ulm  Ulm Germany"},{"name":"Institute of Molecular Oncology and Stem Cell Biology Ulm University Hospital  Ulm Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Macarulla","sequence":"additional","affiliation":[{"name":"Gastrointestinal and Endocrine Tumor Unit Vall d'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d'Hebron  Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Pietrantonio","sequence":"additional","affiliation":[{"name":"Medical Oncology Department Fondazione IRCCS Instituto Nazionale dei Tumori di Milano  Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Casadei\u2010Gardini","sequence":"additional","affiliation":[{"name":"Department of Oncology IRCCS San Raffaele Scientific Institute Hospital, Vita\u2010Salute San Raffaele University  Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,8,26]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.12.010"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu162"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21871"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00727-4"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(24)00095-5"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-024-01060-1"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00027-9"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-0078"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.04.005"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.10.506"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.104003"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2011-0386"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30254"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature09132"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1101\/gad.217406.113"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw013"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30157-1"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.3836"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1177\/17588359231171574"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-022-00917-7"},{"key":"e_1_2_10_22_1","unstructured":"FoundationOne CDX. (2018) https:\/\/www.foundation\u2010medicine.com\/genomic\u2010testing\/foundation\u2010one\u2010cdx."},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2022.08.026"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31598"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15174217"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2020-0429"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206834"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1200\/PO.21.00156"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31829"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-0368"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2017.02.033"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-16-2773"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aaz3221"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aal2463"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-2796"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.34182"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1080\/07357907.2023.2242957"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-022-00933-7"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0095-6"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-21-1077"},{"issue":"9","key":"e_1_2_10_41_1","first-page":"S1454","article-title":"Impact of Mutation Status on Efficacy Outcomes in TOPAZ\u20101: A Phase III Study of Durvalumab (D) or Placebo (PBO) Plus Gemcitabine and Cisplatin (+GC) in Advanced Biliary Tract Cancer (BTC)","volume":"33","author":"Valle J. W.","year":"2022","journal-title":"Annals of Oncology"},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.114199"}],"container-title":["Liver International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/liv.70295","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T14:07:32Z","timestamp":1764598052000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/liv.70295"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,26]]},"references-count":41,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["10.1111\/liv.70295"],"URL":"https:\/\/doi.org\/10.1111\/liv.70295","archive":["Portico"],"relation":{},"ISSN":["1478-3223","1478-3231"],"issn-type":[{"value":"1478-3223","type":"print"},{"value":"1478-3231","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,26]]},"assertion":[{"value":"2025-04-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-09","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-26","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70295"}}